On April 18, 2025, the highly anticipated “China Venture Annual Awards 2024” was officially released. Thanks to the firm’s strategic foresight in backing medical original innovations and its growing influence in early-stage life science investments, Baheal Pharma Group’s investment vehicle—BAHEAL ZHONGXIN CAPITAL—secured a place in the “2024 China Top 50 Corporate Direct‐Investment Funds”, underscoring its professional strength and industry influence in the early-stage life-health investment area.

BAHEAL ZHONGXIN CAPITAL Named to "China's Top 50 Corporate Venture Capitals in CV Awards 2024"

The “CV Awards 2024”, issued by CV Information for the 19th consecutive year, is one of the most authoritative and reference-worthy equity-investment assessments in China. Based on robust data, combined with in-depth research into over a thousand active investment institutions, and undergoing rigorous data verification and institutional evaluation by the CV Research Institute, the list ultimately selects those funds that excel across various investment sub-segments. Because of its professionalism, impartiality and market recognition, the ranking has become a widely acknowledged barometer in the industry and a key reference point for major LP institutions when making capital-allocation decisions.

As an early-stage value investor in China’s life-health sector, BAHEAL ZHONGXIN CAPITAL adheres to its philosophy of “invest early, invest in innovation, invest for the long term”. Operating as an industrial-investment fund, it deploys across three focus tracks—innovative medicines, advanced medical devices, and basic research platforms—discovering and investing in original innovation achievements that possess technological barriers and genuine clinical application value, and promoting their transformation into application. The fund’s portfolio and incubated projects—such as a fully magnetically levitated artificial heart, a medical electron linear accelerator, an electromagnetic-guided puncture navigation device, innovative drugs for nuclear medicine, bone-regeneration and small-nucleic acid innovative drugs—have already made substantial progress toward clinical application, covering major disease fields including cardiovascular diseases and oncology.

At present, BAHEAL ZHONGXIN CAPITAL has become the management platform for biomedical-industry innovation funds across multiple regions, including Beijing, Qingdao, Langfang and Suzhou, managing a total fund size of over tens billions RMB. Centered on the full-lifecycle development needs of innovative enterprises, BAHEAL ZHONGXIN CAPITAL not only provides capital support but also, leveraging Baheal’s capability in industrial-resource integration and incubation, offers multidimensional resource-element allocation—covering R&D, clinical operations, corporate governance and commercialization—continually enhancing the incubation efficiency and translational capacity of innovation projects.

Looking ahead, BAHEAL ZHONGXIN CAPITAL will uphold its mission of optimizing medical scenarios through technological innovation. With a more forward-looking strategic vision and value-investment orientation driving the conversion of scientific achievements, it will continue to support Baheal’s strategic transformation into a technology-driven innovation enterprise and contribute “a wellspring of innovation” to the high-quality development of China’s health industry.